Rocklatan (latanoprost/netarsudil) / Alcon - LARVOL DELTA

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: University of Maryland, Baltimore | Completed ➔ Recruiting | Phase classification: PN/A ➔ P4 | N=10 ➔ 50 | Trial completion date: Feb 2022 ➔ Mar 2027 | Trial primary completion date: Feb 2022 ➔ Mar 2027

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan vs Latanoprost Post-DSLT (clinicaltrials.gov) - P4 | N=36 | Recruiting | Sponsor: Eye Centers of Southeast Texas | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Glaucoma • Ophthalmology

Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study. (PubMed, Clin Ophthalmol) - "A retrospective chart review was performed of eyes diagnosed with OAG, CMG, or ACG and treated with netarsudil (Rhopressa or Rocklatan) between 2018 and 2024 at a single glaucoma specialty clinic in San Jose, California. Netarsudil and its combination therapies demonstrated no significant difference in IOP reduction and tolerability across OAG, CMG, and ACG. These findings support its use as an adjunctive therapy regardless of angle configuration and highlight the need for prospective studies in Asian populations."

Journal • Retrospective data • Glaucoma • Ophthalmology

Shifting Medicare Glaucoma Pharmacotherapy: Rising Costs and Increasing Use of New Mechanism Agents, 2019-2023 (ARVO 2026) - "Results From 2019-2023, utilization of several legacy agents declined sharply (e.g., Travatan Z from 291,097 to 7,534 claims; Combigan from 282,811 to 144,502 claims), while medications with new mechanism of action demonstrated steady growth, including Rhopressa (60,538 to 89,044 claims), Rocklatan (13,994 to 67,255 claims), and Vyzulta (21,280 to 69,308 claims)...Spending (market) shares showed parallel shifts: Lumigan decreased from 54% to 43% and Combigan from 33% to 14%, while medications with new mechanisms of action captured a growing share of total Medicare glaucoma spending – Rhopressa increasing from 7.1% to 10.7%, Rocklatan from 1.1% to 9.0%, and Vyzulta from 2.2% to 7.2%...Total spending rose nearly 50% despite declining overall utilization, underscoring the growing cost burden associated with newer, higher-cost branded agents. These findings highlight the need for cost-conscious prescribing strategies and further evaluation of affordability and access in..."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

Intraocular pressure and trabecular meshwork cytoskeletal effects of latanoprost, latanoprostene bunod and latanoprost–netarsudil (ARVO 2026) - "Our results suggest that the latanoprost–netarsudil combination lowers pressure more quickly and changes the drainage tissue more than the other latanoprost-based drops. This implies that different "upgraded" latanoprost products are not interchangeable, and that pairing latanoprost with a drug that targets the drainage system may offer extra benefit for people who need better eye pressure control."

Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=489 | Completed | Sponsor: Alcon Research | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Phase III Prospective Randomised Study of Netarsudil and Concomitant Latanoprost Efficacy and Safety for Primary Open-Angle Glaucoma or Ocular Hypertension in Japan: J-ROCKET-2. (PubMed, Adv Ther) - "Netarsudil + latanoprost was superior to placebo + latanoprost in lowering elevated IOP in Japanese patients with POAG or OHT. No new safety signals were reported."

Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: Mayo Clinic | Active, not recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Completed | Sponsor: Colorado Ophthalmology Associates PC | Recruiting ➔ Completed

Trial completion • Glaucoma • Ophthalmology

Rocklatan vs Latanoprost Post-DSLT (clinicaltrials.gov) - P4 | N=36 | Not yet recruiting | Sponsor: Eye Centers of Southeast Texas

Monotherapy • New P4 trial • Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=489 | Active, not recruiting | Sponsor: Alcon Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (clinicaltrials.gov) - P4 | N=30 | Active, not recruiting | Sponsor: Mayo Clinic

New P4 trial • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan Retinal Perfusion OCT Study (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Oregon Health and Science University | Initiation date: Oct 2025 ➔ Jan 2026

Trial initiation date • Glaucoma • Ophthalmology

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=426 | Completed | Sponsor: Alcon Research | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan Retinal Perfusion OCT Study (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Oregon Health and Science University

New P4 trial • Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Recruiting | Sponsor: Alcon Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=426 | Active, not recruiting | Sponsor: Alcon Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

Intraocular Pressure Equations Utilizing Aqueous Fluid Flow and Flow Facility in the Steady-State and Time-Dependent Domains. (PubMed, Clin Ophthalmol) - "The steady-state equation was validated by replicating the results of a published IOP efficacy study of combined netarsudil and latanoprost treatment results with a 3% error. Enhanced IOP equations provide a novel framework for modeling IOP dynamics. Potential applications include understanding IOP pathophysiology, evaluating therapeutic interventions, and predicting temporal/diurnal IOP fluctuations."

Journal • Cardiovascular • CNS Disorders • Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Not yet recruiting | Sponsor: Alcon Research

New P3 trial • Cardiovascular • Glaucoma • Ophthalmology

D-optimal candexch algorithm-enhanced machine learning UV-spectrophotometry for five-analyte determination in novel anti-glaucoma formulations and ocular fluids: four-color sustainability framework with NQS assessment and UN-SDG integration. (PubMed, BMC Chem) - "The novel anti-glaucoma ophthalmic preparation containing latanoprost, netarsudil, and benzalkonium chloride has posed a significant challenge due to its complexity and the lack of environmentally sustainable quantification methods, with only a single published method available for its quantification that lacks environmental consideration...Additionally, the method's environmental and societal benefits were further validated using the Need, Quality, Sustainability (NQS) index. Overall, this machine learning-based framework contributes meaningfully to ten United Nations Sustainable Development Goals (UN-SDGs), underscoring its value for future-oriented pharmaceutical research."

Journal • Glaucoma • Ophthalmology

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) (clinicaltrials.gov) - P4 | N=68 | Not yet recruiting | Sponsor: Center for Sight Las Vegas

New P4 trial • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center

New P4 trial • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: Colorado Ophthalmology Associates PC | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology